Genelink Stock Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Genelink are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Genelink has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward-looking signals, Genelink is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Genelink |
Genelink Relative Risk vs. Return Landscape
If you would invest 0.00 in Genelink on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Genelink or generate 0.0% return on investment over 90 days. Genelink is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Genelink, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Genelink Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Genelink for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Genelink can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Genelink generated a negative expected return over the last 90 days | |
| Genelink has some characteristics of a very speculative penny stock | |
| Genelink has accumulated 1.09 M in total debt. Genelink has a current ratio of 0.33, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Genelink until it has trouble settling it off, either with new capital or with free cash flow. So, Genelink's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genelink sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genelink to invest in growth at high rates of return. When we think about Genelink's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.14 M. Net Loss for the year was (3.05 M) with profit before overhead, payroll, taxes, and interest of 464.68 K. | |
| Genelink has accumulated about 127.56 K in cash with (2.38 M) of positive cash flow from operations. |
Genelink Fundamentals Growth
Genelink Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Genelink, and Genelink fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genelink Pink Sheet performance.
| Return On Asset | -0.69 | |||
| Profit Margin | (1.41) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 1.14 M | |||
| Shares Outstanding | 265.02 M | |||
| Price To Earning | (0.07) X | |||
| Price To Sales | 0.25 X | |||
| Revenue | 2.14 M | |||
| EBITDA | (2.11 M) | |||
| Cash And Equivalents | 127.56 K | |||
| Total Debt | 1.09 M | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (2.38 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 1.45 M | |||
About Genelink Performance
Assessing Genelink's fundamental ratios provides investors with valuable insights into Genelink's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Genelink is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
The company was founded in 1994 and is based in Orlando, Florida. GENELINK INC operates under Biotechnology classification in the United States and is traded on PNK Exchange.Things to note about Genelink performance evaluation
Checking the ongoing alerts about Genelink for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Genelink help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genelink generated a negative expected return over the last 90 days | |
| Genelink has some characteristics of a very speculative penny stock | |
| Genelink has accumulated 1.09 M in total debt. Genelink has a current ratio of 0.33, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Genelink until it has trouble settling it off, either with new capital or with free cash flow. So, Genelink's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genelink sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genelink to invest in growth at high rates of return. When we think about Genelink's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.14 M. Net Loss for the year was (3.05 M) with profit before overhead, payroll, taxes, and interest of 464.68 K. | |
| Genelink has accumulated about 127.56 K in cash with (2.38 M) of positive cash flow from operations. |
- Analyzing Genelink's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genelink's stock is overvalued or undervalued compared to its peers.
- Examining Genelink's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genelink's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genelink's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genelink's pink sheet. These opinions can provide insight into Genelink's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genelink Pink Sheet Analysis
When running Genelink's price analysis, check to measure Genelink's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelink is operating at the current time. Most of Genelink's value examination focuses on studying past and present price action to predict the probability of Genelink's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelink's price. Additionally, you may evaluate how the addition of Genelink to your portfolios can decrease your overall portfolio volatility.